logo
  • SELECT LICENSE :

  • US $4,299.00
  • US $8,599.00

Allergy Immunotherapy Market, by immunotherapy Type (SCIT, SLIT), By Type of Allergy (Asthma, Food Allergy, Allergic Rhinitis and Others) opportunities and forecast 2020-2027

  • DLR2104
  • 20 September, 2020
  • Pharma & Healthcare
  • Pages: 120
  • Global
Market Overview

Allergy immunotherapy, hypo-sensitization or desensitization, is a preventive therapeutic treatment for the allergic reactions to various allergens including various drugs, foods, bee venom, house dust mites, and grass pollens. It alters immune system’s reaction by gradually increasing doses of the allergen. Before treatment begins, allergist and patient analyse triggering factors for the allergy symptoms that may involve blood and skin tests to confirm the allergens. The immunotherapy helps in reducing the inflammation, increasing immunological tolerance, offering long-term impact, changing the course of disease and improving quality of the patient’s life.

The rising cases of the allergies are expected to escalate the demand of allergy immunotherapy, leading to high growth of market during the forecast period. As per International Study of Asthma and Allergies in Childhood (ISAAC), around 22.1% of the young children between 13 to 14 years are generally affected by the hay fever. According to the data published by American College of Allergy, Asthma and Immunology (ACAAI), the allergies are sixth leading cause of the chronic illness in the U.S., with annual cost in around USD 18 billion, and over 50 million of the Americans suffer from the allergies each year. There is increase in number of people suffering from various food allergies among both adults and children, globally. Hence, growing burden of these diseases is estimated to aid the demand for new immunotherapies.

Segment Overview

Subcutaneous immunotherapy (SCIT), is most commonly used as well as most effective form of the allergy immunotherapy and is the only treatment accessible that actually changes immune system, making it promising to prevent development of asthma and new allergies. The growing approval of immunotherapy is major factor driving growth of the market.

For instance, in 2018, one of major market players, Stallergenes Greer got approval from theU.S. FDA for the extension of indication for Oralair, allergy immunotherapy sublingual tablet, in order to treat patients of ages 5 to 9 with allergies such as grass pollen-induced rhinitis. Moreover, governments are taking various initiatives to increase awareness about the allergies among population, for instance in January 2018, Ministry and Japanese Society of Allergology opened dedicated website for allergies. Therefore, owing to rising burden of these allergies and awareness among population market is anticipated to witness high growth.

Regional Overview

The U.S. is anticipated to be largest market around the world. High prevalence of such allergies and strict regulatory guidelines which mandate the allergic testing in all cases of emergency and intensive care are some of factors contributing to growth of the U.S. allergy immunotherapy market. It is projected that one among every six people in America (about 50 million) suffers from some or the other form of allergy, and about 25 million people suffer from respiratory allergies. Between the Americans suffering from the respiratory allergies, almost 10 million suffer from the allergic asthma.

In the U.S., ragweed allergy is primary reason for the hay fever (pollen allergies), and the ragweed pollen production is anticipated to increase by around 65% to 100% by 2085. This is gradually contributing to growth of market studied. Moreover, availability of improved healthcare infrastructure is likely driving the growth of the market.

Competitor overview

The market is a consolidated market due to the presence of limited major market players. Some of the major market players include Hollister Allergy, Aimmune Therapeutics, Merck KGaA (Allergopharma), Leti Pharma, Stallergenes Greer, ALK-Abello A/S, HAL Allergy Group, Allergy Therapeutics, Biomay AG, and Circassia

Key Players
  1. Torii Pharmaceutical Co., Ltd.
  2. ALK-Abello A/S
  3. Allergy Therapeutics
  4. Biomay AG
  5. Allovate, LLC
  6. HAL Allergy Group
  7. Hollister Allergy
  8. Leti Pharma
  9. Merck KGaA (Allergopharma)
  10. Stallergenes Greer

Market Segmentation

By Immunotherapy Type
  • SCIT
  • SLIT
By Allergy Type
  • Allergic Rhinitis
  • Food Allergy
  • Asthma
  • Others
By Geography
  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • UAE
    • Rest of LAMEA


1 Report Prologue 14

    2 Market Introduction 18

    • 2.1 Introduction 18
    • 2.2 Scope of Study 18
    • 2.3 Research Objective 19
    • 2.4 Assumptions & Limitations 19
      • 2.4.1 Assumptions 19
      • 2.4.2 Limitations 19
    • 2.5 Market Structure 20

    3 Research Methodology 21

    • 3.1 Research Process 21
    • 3.2 Primary Research 22
    • 3.3 Secondary Research 22
    • 3.4 Market Size Estimation 22
    • 3.5 Forecast Model 24

    4 Market Dynamics 25

    • 4.1 Introduction 25
    • 4.2 Drivers 25
      • 4.2.1 Launch of new sublingual immunotherapies in emerging economies will drive the growth of the market 25
      • 4.2.2 Major players are introducing several allergen immunotherapy tablets (AITs) in potential markets 26
      • 4.2.3 Increase in risk factors causing allergies 26
      • 4.2.4 Rising screening for allergy and reimbursement scenario 26
    • 4.3 Restraint 27
      • 4.3.1 Restricted healthcare spending in underserved market of Europe will restrain the growth 27
    • 4.4 Opportunity 27
      • 4.4.1 Allergy immune therapies will Be Launched in the U.S. 27
    • 4.5 Challenge 28
      • 4.5.1 High Cost of Allergy Immunotherapy 28
    • 4.6 Micro Economic Indicators 28

    5 Market Factor Analysis 30

    • 5.1 Porter’s Five Forces Model 30
      • 5.1.1 Bargaining Power of Suppliers 31
      • 5.1.2 Bargaining Power of Buyers 31
      • 5.1.3 Threat of New Entrants 31
      • 5.1.4 Threat of Substitutes 31
      • 5.1.5 Intensity of Rivalry 31
    • 5.2 Supply Chain Analysis 32
      • 5.2.1 R&D 32
      • 5.2.2 Parts Manufacturing 33
      • 5.2.3 Distribution 33
      • 5.2.4 Marketing & Sales 33
      • 5.2.5 Post-Sales Monitoring 33
    • 5.3 Pricing Analysis 33
    • 5.4 Investment Opportunity Analysis 34
    • 5.5 Merger and Acquisition Landscape 35

    6 Global Allergy Immunotherapy Market, By Type of therapy 36

    • 6.1 Subcutaneous immunotherapy (SCIT) 37
    • 6.2 Sublingual Immunotherapy (SLIT) 38

    7 Global Allergy Immunotherapy Market, By Types Of Allergies 39

    • 7.1 Rhinitis 40
    • 7.2 Asthma 40
    • 7.3 Eye allergy 41
    • 7.4 Skin allergy 41

    8 Global Allergy Immunotherapy Market, By End User 42

    • 8.1 Hospitals 43
    • 8.2 Clinics 43
    • 8.3 Diagnostic centers 44

    9 Global Allergy immunotherapy Market, By Region 45

    • 9.1 Americas 46
      • 9.1.1 North America 48
        • 9.1.1.1 US 51
        • 9.1.1.2 Canada 53
      • 9.1.2 Latin America 55
        • 9.1.2.1 Brazil 57
        • 9.1.2.2 Mexico 59
        • 9.1.2.3 Argentina 61
        • 9.1.2.4 Columbia 63
        • 9.1.2.5 Chile 64
        • 9.1.2.6 Rest of Latin America 66
      • 9.1.3 South America 67
        • 9.1.3.1 Bolivia 70
        • 9.1.3.2 Ecuador 73
        • 9.1.3.3 Peru 75
        • 9.1.3.4 Venezuela 77
        • 9.1.3.5 Uruguay 78
  • 9.2 Europe 80
    • 9.2.1 Western Europe 82
      • 9.2.1.1 Germany 84
      • 9.2.1.2 France 86
      • 9.2.1.3 UK 88
      • 9.2.1.4 Italy 90
      • 9.2.1.5 Spain 92
      • 9.2.1.6 Russia 94
      • 9.2.1.7 Rest of Western Europe 96
    • 9.2.2 Central Europe 97
      • 9.2.2.1 Switzerland 99
      • 9.2.2.2 Slovenia 101
    • 9.2.3 Eastern Europe 103
    • 9.2.4 Greece 105
    • 9.2.5 Rest of Eastern Europe 107
  • 9.3 Asia Pacific 109
    • 9.3.1 Japan 111
    • 9.3.2 China 113
    • 9.3.3 India 115
    • 9.3.4 Republic of Korea 117
    • 9.3.5 Australia 118
    • 9.3.6 New Zealand 120
  • 9.4 Middle East & Africa 121
  • 9.5 Middle East 124
  • 9.6 Africa 125
  • 10 Company Landscape 127

    • 10.1 Introductions 127

    11 Company Profile 129

    • 11.1 ALK Abello A/S 129
      • 11.1.1 Overview 129
      • 11.1.2 Product/Business Overview 129
      • 11.1.3 Financial Overview 129
      • 11.1.4 Key Development 131
      • 11.1.5 SWOT Analysis 131
    • 11.2 Allergy Therapeutics 132
      • 11.2.1 Company Overview 132
      • 11.2.2 Product/Business Segment Overview 132
      • 11.2.3 Financial Overview 132
      • 11.2.4 Key Development 133
      • 11.2.5 SWOT Analysis 134
    • 11.3 Circassia 135
      • 11.3.1 Company Overview 135
      • 11.3.2 Product/Business Segment Overview 135
      • 11.3.3 Financial Overview 135
      • 11.3.4 Key Development 136
      • 11.3.5 SWOT Analysis 137
    • 11.4 DBV Technologies 138
      • 11.4.1 Company Overview 138
      • 11.4.2 Product/Business Segment Overview 138
      • 11.4.3 Financial Overview 138
      • 11.4.4 Key Development 139
      • 11.4.5 SWOT Analysis 139
    • 11.5 Stallergenes Greer 140
      • 11.5.1 Company Overview 140
      • 11.5.2 Product/Business Segment Overview 140
      • 11.5.3 Financial Overview 140
      • 11.5.4 Key Development 142
      • 11.5.5 SWOT Analysis 142
    • 11.6 Merck KGaA (Allergopharma) 143
      • 11.6.1 Company Overview 143
      • 11.6.2 Product/Business Segment Overview 143
      • 11.6.3 Financial Overview 144
      • 11.6.4 Key Development 145
      • 11.6.5 SWOT Analysis 145
    • 11.7 HAL Allergy Group 146
      • 11.7.1 Company Overview 146
      • 11.7.2 Product/Business Segment Overview 146
      • 11.7.3 Financial Overview 146
      • 11.7.4 Key Development 146
      • 11.7.5 SWOT Analysis 147

    12 Conclusion 148

    • 12.1 Key Findings 148
      • 12.1.1 From CEO’s View Point 148
    • 12.2 Key Companies To Watch 148

    13 Appendix 149

    Report You Might be Interested